Business Description

West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Share Class Description:
WST: Ordinary SharesDescription
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.93 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.38 | |||||
Interest Coverage | 73.48 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 20.72 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16 | |||||
3-Year EBITDA Growth Rate | 25.8 | |||||
3-Year EPS without NRI Growth Rate | 38.4 | |||||
3-Year FCF Growth Rate | 22 | |||||
3-Year Book Growth Rate | 19.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.01 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.28 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.97 | |||||
9-Day RSI | 56.14 | |||||
14-Day RSI | 51.82 | |||||
6-1 Month Momentum % | -5.81 | |||||
12-1 Month Momentum % | 32.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.7 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 1.68 | |||||
Days Inventory | 86.8 | |||||
Days Sales Outstanding | 63.85 | |||||
Days Payable | 43.31 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.22 | |||||
Dividend Payout Ratio | 0.1 | |||||
3-Year Dividend Growth Rate | 6.2 | |||||
Forward Dividend Yield % | 0.23 | |||||
5-Year Yield-on-Cost % | 0.3 | |||||
Shareholder Yield % | 0.63 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 38.04 | |||||
Operating Margin % | 23.85 | |||||
Net Margin % | 19.12 | |||||
FCF Margin % | 14.35 | |||||
ROE % | 20.65 | |||||
ROA % | 15.47 | |||||
ROIC % | 23.55 | |||||
ROC (Joel Greenblatt) % | 35.83 | |||||
ROCE % | 21.51 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 47.48 | |||||
Forward PE Ratio | 40.32 | |||||
PE Ratio without NRI | 43.86 | |||||
Shiller PE Ratio | 74.5 | |||||
Price-to-Owner-Earnings | 45.66 | |||||
PEG Ratio | 1.85 | |||||
PS Ratio | 9.07 | |||||
PB Ratio | 9.08 | |||||
Price-to-Tangible-Book | 9.48 | |||||
Price-to-Free-Cash-Flow | 63.18 | |||||
Price-to-Operating-Cash-Flow | 34.55 | |||||
EV-to-EBIT | 38.08 | |||||
EV-to-Forward-EBIT | 31.97 | |||||
EV-to-EBITDA | 31.78 | |||||
EV-to-Forward-EBITDA | 27.27 | |||||
EV-to-Revenue | 8.69 | |||||
EV-to-Forward-Revenue | 7.93 | |||||
EV-to-FCF | 60.56 | |||||
Price-to-Projected-FCF | 3.93 | |||||
Price-to-DCF (Earnings Based) | 1.4 | |||||
Price-to-DCF (FCF Based) | 2.02 | |||||
Price-to-Median-PS-Value | 1.87 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.84 | |||||
Price-to-Graham-Number | 4.3 | |||||
Price-to-Net-Current-Asset-Value | 23.98 | |||||
Price-to-Net-Cash | 2198.69 | |||||
Earnings Yield (Greenblatt) % | 2.63 | |||||
FCF Yield % | 1.61 | |||||
Forward Rate of Return (Yacktman) % | 21.21 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:WST
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
West Pharmaceutical Services Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2,926.5 | ||
EPS (TTM) ($) | 7.41 | ||
Beta | 1.12 | ||
Volatility % | 36.8 | ||
14-Day RSI | 51.82 | ||
14-Day ATR ($) | 7.984881 | ||
20-Day SMA ($) | 345.1865 | ||
12-1 Month Momentum % | 32.91 | ||
52-Week Range ($) | 224.1546 - 415.73 | ||
Shares Outstanding (Mil) | 73.99 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
West Pharmaceutical Services Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
West Pharmaceutical Services Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
West Pharmaceutical Services Inc Frequently Asked Questions
What is West Pharmaceutical Services Inc(WST)'s stock price today?
The current price of WST is $351.79. The 52 week high of WST is $415.73 and 52 week low is $224.15.
When is next earnings date of West Pharmaceutical Services Inc(WST)?
The next earnings date of West Pharmaceutical Services Inc(WST) is 2024-02-16 Est..
Does West Pharmaceutical Services Inc(WST) pay dividends? If so, how much?
The Dividend Yield %  of West Pharmaceutical Services Inc(WST) is 0.22% (As of Today), Highest Dividend Payout Ratio of West Pharmaceutical Services Inc(WST) was 0.26. The lowest was 0.08. And the median was 0.21. The  Forward Dividend Yield % of West Pharmaceutical Services Inc(WST) is 0.23%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |